Abstract
Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.
MeSH terms
-
Clopidogrel
-
Cytochrome P-450 Enzyme System / genetics*
-
Genetic Testing / methods*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Pharmacogenetics / methods*
-
Psychotropic Drugs / pharmacology
-
Tamoxifen / pharmacology
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / pharmacology
-
Warfarin / pharmacology
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Psychotropic Drugs
-
Tamoxifen
-
Warfarin
-
Cytochrome P-450 Enzyme System
-
Clopidogrel
-
Ticlopidine